Evidence for chronic lung impairment in patients treated for pulmonary tuberculosis

Mauricio Vecino, Jotam G. Pasipanodya, Philip Slocum, Sejong Bae, Guadalupe Munguia, Thaddeus L. Miller, Michel Fernandez, Gerry Drewyer, Stephen Weis

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Background: Patients with pulmonary tuberculosis are likely to develop pulmonary impairment after tuberculosis (PIAT). The stability of PIAT and the relationship of PIAT to the duration of delay in tuberculosis diagnosis and treatment have not been fully characterized. Methods: We performed serial pulmonary function tests (PFTs) in a cohort treated for pulmonary tuberculosis after 20 weeks of tuberculosis therapy and again on or after treatment completion to determine the stability of PIAT. PFTs were compared with the duration of delay in tuberculosis diagnosis and treatment, as well as other demographic variables. Results: The median duration between the first and second tests was 15 (interquartile range 9-34) weeks. The mean change in FVC was -0.02. l (95% confidence interval [CI] -0.09, 0.06), and the % predicted was -0.02 (95% CI -2.17, 2.12). FEV1 changes were 0. l (95% CI -0.05, 0.06), and the % predicted was -0.11 (95% CI -1.82, 1.60). PIAT was not related to the duration of delay in tuberculosis diagnosis or treatment, age or smoking. Conclusions: PIAT was not associated with the duration of delay in tuberculosis diagnosis and treatment and did not significantly change during follow-up. These data demonstrate that, for many individuals, the completion of tuberculosis treatment is the beginning, not the end, of their tuberculosis illness.

Original languageEnglish
Pages (from-to)244-252
Number of pages9
JournalJournal of Infection and Public Health
Volume4
Issue number5-6
DOIs
StatePublished - 1 Nov 2011

Keywords

  • Disability
  • Health policy
  • Pulmonary function tests
  • Pulmonary impairment
  • Tuberculosis

Fingerprint Dive into the research topics of 'Evidence for chronic lung impairment in patients treated for pulmonary tuberculosis'. Together they form a unique fingerprint.

  • Cite this